# Lyell Immunopharma (stock symbol: LYEL) Logo in transparent PNG and SVG formats

## Lyell Immunopharma Logo large

### Lyell Immunopharma Logo large Download PNG (98.7 KB)

![Lyell Immunopharma Logo large Download PNG (98.7 KB)](/img/orig/LYEL_BIG-f61ec377.png)

### Lyell Immunopharma Logo large Download SVG (4.81 KB)

![Lyell Immunopharma Logo large Download SVG (4.81 KB)](/img/orig/LYEL_BIG-efb1ab94.svg)

## Lyell Immunopharma Logo icon format

### Lyell Immunopharma Logo icon format Download PNG (120.69 KB)

![Lyell Immunopharma Logo icon format Download PNG (120.69 KB)](/img/orig/LYEL-34852d67.png)

### Lyell Immunopharma Logo icon format Download SVG (3.9 KB)

![Lyell Immunopharma Logo icon format Download SVG (3.9 KB)](/img/orig/LYEL-605312fb.svg)

## Lyell Immunopharma Logo large for dark backgrounds

### Lyell Immunopharma Logo large for dark backgrounds Download PNG (98.64 KB)

![Lyell Immunopharma Logo large for dark backgrounds Download PNG (98.64 KB)](/img/orig/LYEL_BIG.D-7a731c4e.png)

### Lyell Immunopharma Logo large for dark backgrounds Download SVG (4.81 KB)

![Lyell Immunopharma Logo large for dark backgrounds Download SVG (4.81 KB)](/img/orig/LYEL_BIG.D-158f156d.svg)

## Lyell Immunopharma Logo icon format for dark backgrounds

### Lyell Immunopharma Logo icon format for dark backgrounds Download PNG (119.9 KB)

![Lyell Immunopharma Logo icon format for dark backgrounds Download PNG (119.9 KB)](/img/orig/LYEL.D-fa9ff70e.png)

### Lyell Immunopharma Logo icon format for dark backgrounds Download SVG (3.9 KB)

![Lyell Immunopharma Logo icon format for dark backgrounds Download SVG (3.9 KB)](/img/orig/LYEL.D-90459620.svg)

## About Lyell Immunopharma

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

1. Website domain: lyell.com
2. Employees: 219
3. Marketcap: $0.50 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
